Onto Innovation
This is the archived full research. Read the story
Instruments that measure and inspect chips mid-manufacture without touching them, so a chip factory learns a wafer is bad before paying for the next step.
The scores
Growth3/4 ↑
Revenue grew 1.8% in FY2025 with Semilab inside it, then 22.1% in the first half of 2026. Real, but under two years and partly acquired.
Business quality2/4 ↓
Qualification-led positions at 190 customers argue for 3, but systems revenue fell in the boom year and margins are half the cohort's.
Financial position3/4 ↓
Zero-coupon notes maturing outside the horizon and strong operating cash, but $1.5 billion of new debt replaced a debt-free balance sheet.
Execution record2/4 ↑
The third quarter beat its GAAP guide and non-GAAP guide, but the first quarter's GAAP miss stands and charges are guided up.
Per share capture3/4 →
Share count up 1.4% and acquisitions paid in cash, with a capped call well above the conversion price. Buybacks do not quite outrun compensation.
Potential2/4 ↑
The upside is a bounded cycle: contracts yet to convert and somebody else's capital plans, with the largest agreements conditional and unfiled.
Risk profile3/4 →
Three customers are 49% of revenue and China export controls bind, but the concentration is disclosed, falling, and no single event resolves the case.
Valuation2/4 →
About 48 times operating profit, 130% of a three-stage value near $149 at 8%: full, beyond the 20% margin.
Evidence quality3/4 →
The restructuring table, the reconciliations and the cohort are all filed primary sources, but the backlog is a quote and the latest call is unread.
The Verdict
We rate Onto Unattractive. It sells tools that inspect chips mid-manufacture, so a factory spots a bad wafer early, and sales are booming at a record margin. But it has booked restructuring charges four years running and guides a fifth, lost ground in packaging inspection and holds a large minority stake outside its control, so the business is mixed. On profit the price is above its rivals' and about 30% above our value even on a fast path, needing more than the record margin holding. The charges ending would change the view.
The long caseAI spending is building new chip factories, which install inspection tools first; Onto rides only a small slice of that, and its reported margins must still rise.
How we weighed it
The price against our value
Against it
Price at 130% of our value
The price sits above our value on a fast path, though the bull case is higher.
The business
Cuts both ways
Mixed
A mixed business: a record margin, but charges that never end.
Growth against what the price assumes
In its favour
Sales are booming and the margin test passed.
What could go wrong
Against it
Charges recur, it lost ground in packaging inspection and a large minority bet sits outside its control.
Against competitors
Cuts both ways
Above the group on operating profit as last checked, though rivals are not yet refreshed.
How its group is behaving
Cuts both ways
Chip-equipment names move together on news about chipmakers' spending.
The latest news and report
In its favour
The last report passed the margin test, though charges are guided up.
The evidence under this - 8 claims
- 2026-11-09editedQ3 2026 release: nine-month figure and the higher fourth-quarter guide
- Annualising the third-quarter GAAP operating income guide of $81.4-89.7 million gives roughly 26 times company value at the 6 November close and 29 at the 9 November one, below the cohort's trailing median of 35. If the guided quarter is the run rate the premium is already gone.
- The notes are convertible and an if-converted reading would swap $1.5B of debt for about 3.9 million shares; the 10-Q says the notes were not in the money at 30 September, so they are carried as debt here.
- 2026-11-05editedRe-struck at the 2026-11-04 close from a pack fetched 2026-11-05: EV/EBIT 66.4 against a cohort median of 35.3, from 96.9 against 45.0 at 2026-09-04. The cohort fell about 22% in the same weeks, so the gap narrowed from 2.2 times to 1.9 times.
- 2026-11-09editedre-struck at the 6 November close after the Q3 print lifted trailing operating income to $206M
- 2026-11-10editedCompany value now includes the $1.5B of 2031 convertible notes the 9 November version left out of the bridge; 35 times was struck on cash alone
- 2026-11-05editedRe-struck at the 2026-11-04 close of 184.82 from a pack fetched 2026-11-05 (price down 31% from 268.01): EV/EBIT 66.4 against a cohort median of 35.3, nearly twice rather than more than twice; still cheapest on price to sales and to book.
- 2026-11-09editedre-struck at the 6 November close on trailing operating income of $206M after the Q3 print; cohort medians not refreshed
- 2026-11-10editedThe 35 times it quoted left the $1.5B of convertible notes out of company value; with them Onto is about 43 times at the 6 November close, above the cohort median
- The company guided first-quarter 2026 GAAP diluted EPS to $0.74-$0.84 and delivered $0.67, below its own range, while the non-GAAP figure beat its range - so the GAAP half of this guidance has missed once in the last two quarters it was given.
- Restructuring has been guided as ending, and has instead risen in each of the last three fiscal years.
- 2026-11-05editedIts valid_through of 2026-11-05 comes before the print: the company dates Q3 results to 9 November (release of 2026-10-19; FMP calendar), so the guide stands until then.
- 2026-11-09editedthe print answered the guide: margin above the band and restructuring below it
- 2026-11-09editedRe-struck on the decaying fade the owner chose on 9 November: after the stated path each year closes 30% of the gap to 4%, and an analysts' margin is cut by their gap to the filed operating profit.
The company
A chip passes through hundreds of steps, and a flaw made early is often found only at the final test, after every later step has been paid for. Onto's instruments shine light at a wafer and work backwards from what returns to measure layers too thin to see, or photograph the whole wafer to spot defects.
It also sells machines that print patterns onto chip packages, and software that turns the readings into decisions. Its newest inspection tool sees details below 200 nanometres, against about 800 in the past.
The evidence under this - 3 claims
- The customer is not named and the win is not quantified; management said G5 was under 10% and perhaps 5% of advanced packaging growth in 2026.
- Camtek and KLA sell competing advanced-packaging inspection and neither has disclosed losing this position.
How it makes money
Onto is paid mainly when a chipmaker buys a tool, and chipmakers buy when they build new production lines, so orders follow their building plans. Three unnamed customers took 49% of 2025 sales.
The evidence under this - 2 claims
Where the money comes from, stream by stream
| Stream | Share of sales (first half of 2026) | How it earns it |
|---|---|---|
| Systems and software | 85.2% | Metrology, inspection and packaging-lithography tools plus yield software, recognised mostly when a tool ships or is accepted. |
| Parts | 8.7% | Spare parts for the installed base of tools, sold as customers run and upgrade them. |
| Services | 6.1% | Service contracts and field support on installed tools, recognised over the contract term. |
Who runs it
Michael Plisinski has run Onto since it was formed by a 2019 merger; Brian Roberts became finance chief in 2025. Sales have nearly doubled under Plisinski, but cleanup charges have risen four years running. Insiders own about 0.5% of the company. The bonus rides on sales and on profit before those charges, and half the shares on how the stock does against other chip companies.
The evidence under this - 3 claims
- The operating-income goal is struck after adding back $63.4 million of restructuring and $39.4 million of amortisation, so the charges this thesis turns on (C06) cost the bonus nothing.
- FY2025 revenue of $1,005.3 million fell short of the $1,100.0 million target, so the plan did pay below target when the business missed.
Why it wins, and who could beat it
Why customers come back
A tool is approved for one named step at one named customer, and its recipes and library of known defects are built against that customer's process over months. Replacing it means re-approving the step, not swapping a box. KLA, the industry giant, names Onto as a competitor in its own annual report, and Onto holds 423 patents.
The weak spot showed in 2025: tool sales fell as fewer inspection units shipped for AI chip packaging, a market that was growing.
The evidence under this - 4 claims
The threat
KLA sells into the same factories and earned $12.2B from this kind of equipment last year, at a 41.7% operating margin. Camtek and Nova sell to the same chipmakers, and Camtek gets about half its sales from AI, including the packaging market where Onto's inspection sales fell.
The evidence under this - 3 claims
- Camtek's revenue is a fifth of Onto's, so it can grow off a smaller base without Onto losing absolute share.
- Onto's own advanced packaging revenue reached a record in the second quarter of 2026, so whatever happened in FY2025 has reversed at least once.
The rivals: KLAC, CAMT, NVMI, PDFS, and 1 more that is private, in-house or listed abroad.
Who else does this, rival by rival
| Ticker | Rival | How far along | Priced against it |
|---|---|---|---|
| KLAC | KLA CorporationPriced against it: Yes | On sale | Yes |
| CAMT | Camtek Ltd.Priced against it: Yes | On sale | Yes |
| NVMI | Nova Ltd.Priced against it: Yes | On sale | Yes |
| GigaVis Co. Ltd.Priced against it: Listed abroad | On sale | Listed abroad | |
| PDFS | PDF SolutionsPriced against it: One segment only | On sale | One segment only |
How big it could get
How big this could get
Chipmakers are forecast to spend $143.9B on factory equipment in 2026, up 23.1%. Measuring and inspection is about a tenth of that: four listed suppliers sell at least $14.6B a year of it, and KLA alone is $12.2B. Nobody publishes the exact size, so that is a floor, not the market.
The evidence under this - 3 claims
- SEMI's own December 2025 forecast had wafer fab equipment growing 9.0% in 2026; the mid-year revision to 23.1% is a large move in seven months and the series is a forecast, not a measurement.
- A forecast published by the industry's trade association is made by an organisation whose members benefit from the spending it projects.
- Three of the suppliers KLA names - Applied Materials, Hitachi High-Tech and Lasertec - publish no process-control line, so the true market is larger than this sum by an unknown amount.
- The periods do not align: KLA's year ends in June, the others in December or January, and the wafer fab equipment figure is a calendar-2026 forecast.
Who has signed
The backlog passed $1B in June, a figure that appears in a quote from the chief executive but not in the accounts. The largest single deal is a purchase agreement worth over $240M with an unnamed maker of high-bandwidth memory chips, supporting its expansion through 2027.
The evidence under this - 2 claims
- Onto tags no remaining performance obligation in its XBRL and discloses no backlog table, so the figure cannot be checked against anything filed.
- A semiconductor equipment backlog is an order book customers can move or cancel; Onto's own risk factors describe fluctuating customer capital spending.
- 2026-11-09editedQ3 2026 release raised the backlog figure to more than $1.3 billion
- The counterparty is not named, the agreement is not filed as an exhibit, and the value is described as an estimate rather than a committed minimum.
- A volume purchase agreement in semiconductor equipment typically sets pricing against expected volumes rather than obliging the buyer to take them.
Where the growth is coming from, business by business
Where the growth is coming from
| Business | Share of revenue | Growth: last quarter | Last half-year | Last year |
|---|---|---|---|---|
| Systems And Software Revenue | 87% | +106.2% | +68.0% | +28.3% |
| Parts Revenue | 7% | +19.0% | +30.6% | +31.4% |
| Service Revenue | 6% | +12.2% | +9.1% | +13.9% |
| Whole company | 100% | +87.8% | +59.6% | +27.5% |
The filed split through 2026-09-30. These rates are not carried forward: the reading below says why.
How we read it: The score believes neither the 23% the mix implies nor the 8% trailing: the half-year rate includes Semilab, bought November 2025, and laps a weak 2025 base; excluding Semilab, first-half growth was about 13%.
The results
The numbers
Sales grew 31% over the twelve months to Sep 2026, faster than the 1.8% in the year to Jan 2026.
Operating margin is 16%, about where it was (14%) in the year to Dec 2023.
Running costs take 36¢ of each sales dollar, down from 74¢ in the year to Jan 2022.
Each dollar put into the business earns 6.0% a year after tax, down from 14% in the year to Dec 2022.
It turned 19% of sales into free cash, $248M over the last twelve months.
Yearly sales growth has ranged from −19% to +42% over the last 5 years, with sales falling in 1 of them.
The share count fell 0.9% in 4.7 years, and pay in shares costs 2.5% of sales.
All the numbers
Filed figures from the company's 10-K and 10-Q, read 2026-11-10. Fiscal years end in January.
| Jan 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Jan 2026 | 12 mo to Sep 2026 | |
|---|---|---|---|---|---|---|
| Size and growth | ||||||
| Sales | $789M | $1.01B | $816M | $987M | $1.01B | $1.31B |
| Sales growth | +42% | +27% | −19% | +21% | +1.8% | +31% |
| Profit | ||||||
| Gross margin | 54% | 54% | 52% | 52% | 50% | 52% |
| Operating margin | −20% | 24% | 14% | 19% | 13% | 16% |
| Net margin | 18% | 22% | 15% | 20% | 14% | 12% |
| What growth costs, per sales dollar | ||||||
| Research and development | 12% | 11% | 13% | 12% | 13% | 12% |
| Sales and marketing | 7.3% | 6.5% | 7.6% | 7.7% | 7.0% | 6.6% |
| General and admin | 8.6% | 6.9% | 9.8% | 8.1% | 11% | 11% |
| Pay in shares | 2.5% | 2.4% | 3.1% | 2.9% | 2.7% | 2.5% |
| Capital spending | 1.5% | 1.8% | 2.8% | 3.2% | 2.8% | 1.1% |
| Cash | ||||||
| Cash from operations | $175M | $137M | $172M | $246M | $328M | $262M |
| Free cash flow | $163M | $118M | $149M | $214M | $300M | $248M |
| Balance sheet | ||||||
| Cash and short-term investments | $511M | $548M | $698M | $852M | $640M | $1.25B |
| Debt | - | - | - | - | - | $1.50B |
| Net cash | - | - | - | - | - | −$249M |
| Returns and shares | ||||||
| Return on capital | - | 14% | 6.4% | 9.3% | 5.5% | 6.0% |
| Shares (diluted) | 49.7M | 49.8M | 49.3M | 49.7M | 49.3M | 49.3M |
What growth costs
Growth has not yet made Onto more profitable: sales have risen strongly, but spending on research, selling and running the company rose just as fast, partly because of the business it bought. Cleanup charges and the cost of past deals sit on top.
The evidence under this - 2 claims
Semilab USA, bought in November 2025, brought its own costs with it (C10, C36), so part of the FY2025 and trailing rise is the acquired business rather than organic spending.
- 2026-11-09editedQ3 2026 release: nine-month figure and the higher fourth-quarter guide
The last report (9 Nov)
Quarter ended September 2026, filed figures.
The third quarter of 2026 was a record: sales of $409.7M, up 87.8%, and reported operating profit of $95.4M, a 23.3% margin against the 21.4% to 22.4% promised. Restructuring was $12.1M, below the $15M to $17M promised.
The catch is the next quarter. The company guides $18M to $22M of restructuring for the December quarter, which would take 2026 above $60M. Backlog rose to more than $1.3B.
On the call, management expects sales to rise each quarter into 2027 and gross margin to gain about half a point a quarter. It did not say when the charges end, and no analyst asked.
What it did to the thesisThe margin test passed and the business is stronger than the thesis expected. Charges are guided up rather than down, and the return on money invested is unproven.
The quarter in detail
Sales growth from the previous quarter, filed figures.
Earnings per share $2.44 against $2.30 expected.
The evidence under this - 6 claims
- 2026-11-09editedRe-struck on the decaying fade the owner chose on 9 November: after the stated path each year closes 30% of the gap to 4%, and an analysts' margin is cut by their gap to the filed operating profit.
- The company guided first-quarter 2026 GAAP diluted EPS to $0.74-$0.84 and delivered $0.67, below its own range, while the non-GAAP figure beat its range - so the GAAP half of this guidance has missed once in the last two quarters it was given.
- Restructuring has been guided as ending, and has instead risen in each of the last three fiscal years.
- 2026-11-05editedIts valid_through of 2026-11-05 comes before the print: the company dates Q3 results to 9 November (release of 2026-10-19; FMP calendar), so the guide stands until then.
- 2026-11-09editedthe print answered the guide: margin above the band and restructuring below it
- 2026-11-09editedQ3 2026 release: nine-month figure and the higher fourth-quarter guide
- The company's GAAP guide missed once in the last two quarters it was given, in the first quarter, and met it in the third.
- Restructuring was guided to fall and has instead risen in each of four years; $18-22 million is above the third quarter's $12.1 million.
- 2026-11-09editedRe-struck on the decaying fade the owner chose on 9 November: after the stated path each year closes 30% of the gap to 4%, and an analysts' margin is cut by their gap to the filed operating profit.
- 2026-11-09editedthe business re-valued in three stages at an 8% required return, with analysts' margins put on the filed basis, after the day's review
- Onto tags no remaining performance obligation in its XBRL and discloses no backlog table, so the figure cannot be checked against anything filed.
- A semiconductor equipment backlog is an order book customers can move or cancel; Onto's own risk factors describe fluctuating customer capital spending.
- 2026-11-09editedQ3 2026 release raised the backlog figure to more than $1.3 billion
- Operating margin quoted on the call (32.6% for the quarter, 34% guided) is the non-GAAP one; the GAAP figures are 23.3% and 24.4%-24.8%, and the gap is the amortisation and restructuring this thesis is about.
- The call is a company's account of its own order book, which customers can move; the analyst who asked about reports of push-outs and de-specification at memory-stack customers was answered with 'as long as the wafer content stays the same or more'.
What management did with the money
It borrowed $1.5B through notes that pay no interest and turn into shares at $381.80, then spent about $720M on 27% of Rigaku, a company it does not control. It also bought back $205M of stock, yet the share count still rose, to 49.7 million from 49.0 million.
Insiders in 2026Q3: 0 purchases and 4 sales, from their Form 4 filings.
The evidence under this - 3 claims
- Management framed the stake as self-funding: foregone interest income offset by licensing revenue plus about $7 million of Rigaku dividends.
- The stake buys access to X-ray metrology that Onto's own chief executive placed several device generations out, so the operating return is deferred rather than absent.
The price, and where we disagree
In short. Full. The price is about 130% of what we think the business is worth, at an 8% yearly return.
The shares gained over the past year but fell 31% from early September to 4 November. The September quarter has now passed its test, and the next test is the full-year report in February 2027, with a December analyst event before it.
The same kind of promise missed once in the March quarter, when reported earnings per share fell short of guidance while the adjusted figure beat it.
The evidence under this - 2 claims
- The company's GAAP guide missed once in the last two quarters it was given, in the first quarter, and met it in the third.
- Restructuring was guided to fall and has instead risen in each of four years; $18-22 million is above the third quarter's $12.1 million.
- 2026-11-09editedRe-struck on the decaying fade the owner chose on 9 November: after the stated path each year closes 30% of the gap to 4%, and an analysts' margin is cut by their gap to the filed operating profit.
- 2026-11-09editedthe business re-valued in three stages at an 8% required return, with analysts' margins put on the filed basis, after the day's review
How we value it
- Method
- Cash the business will produce, in three stages
- Required return
- 8%
- Long-run growth
- 4%
- Moat
- No moat
| Bear | Base | Bull | |
|---|---|---|---|
| Sales growth, years 1 to 3 | 16.9%, 10%, 9.5% | 33.8%, 19.9%, 18.9% | 42.3%, 24.9%, 23.6% |
| Normal operating margin | 21.2% | 26.6% | 29.2% |
| Return on new capital after year ten | 8% | 8% | 11% |
| Value a share | $78.83 | $149 | $250 |
- Price
- $194
- Priced on
- 9 Nov
- Price as a share of the base value
- 130%
- Starting growth the price pays for
- 44.6%
- Yearly return the price offers on the base case
- 7.1%
- Risk check: valued at 10%, the rate for a cyclical or indebted business
- $110
Where each figure comes from
| Figure | Source | Where exactly |
|---|---|---|
| Sales, the last twelve months | Filed report | Quarterly report (10-Q) for the period to 30 Sep 2026, filed 9 Nov 2026; the four quarters to that date. |
| Operating margin today | Filed report | Quarterly report (10-Q) for the period to 30 Sep 2026, filed 9 Nov 2026; the four quarters to that date. |
| Tax rate | Filed report | Quarterly report (10-Q) for the period to 30 Sep 2026, filed 9 Nov 2026; the four quarters to that date. |
| Sales per dollar of new capital | Filed report | Annual report (10-K) for the period to 3 Jan 2026, filed 24 Feb 2026: the year's sales over its operating capital. |
| Shares | Filed report | Quarterly report (10-Q) for the period to 30 Sep 2026, filed 9 Nov 2026; the diluted share count. |
| Cash and investments | Filed report | Quarterly report (10-Q) for the period to 30 Sep 2026, filed 9 Nov 2026; the balance sheet on that date. |
| Debt | Filed report | Quarterly report (10-Q) for the period to 30 Sep 2026, filed 9 Nov 2026; the balance sheet on that date. |
| Sales growth, years 1 to 3 | Analysts' forecasts | FMP's consensus for the years to 3 Jan 2027, 3 Jan 2028 and 3 Jan 2029, as it stood when the value was struck on 10 Nov 2026: the average of 5 to 10 analysts' revenue estimates, 33.8%, 19.9%, 18.9%. FMP publishes how many analysts, not who they are. |
| Normal operating margin | Analysts' forecasts | FMP's consensus operating margin for the year to 3 Jan 2029, the average of 10 analysts' estimates, 36.5%, less stock pay of 2.5% of sales and less the 7.1% the analysts add back on their adjusted basis: 26.9%, which the base case takes as 26.6%. FMP publishes how many analysts, not who they are. |
| Return on new capital after year ten | Our method's rule | Set by our reading of the moat: the 8% rate with none, 12% with an average one, 15% with a strong one; the bear case earns the rate. |
| The bear and bull cases | Our method's rule | Our method's spread: the bear case takes half the growth and a fifth off the margin, the bull a quarter more growth and a tenth more margin. |
| Price | Market price | FMP's closing price on 9 Nov 2026. |
What each case rests on
Bear caseGrowth runs at half the analysts' path, 17%, 10% and 10%, the margin settles a fifth lower at 21.2%, and new capital earns only the 8% rate: the downturn test.
Base caseRevenue grows 34%, 20% and 19% over three years, the analysts' path (C47) measured from the twelve months to September, then fades toward 4%, closing 30% of the gap each year; the margin moves to 26.6%, the analysts' year-three figure after stock pay and on the filed basis.
Bull caseGrowth runs a quarter above the analysts' path, 42%, 25% and 24%, the margin reaches 29.2%, and new capital earns 11%.
What moves the base value
| Lower | Higher | |
|---|---|---|
| Growth in years 1 to 3, a quarter lower or higher | $123 | $180 |
| The normal margin, 15% lower or higher | $124 | $174 |
| Capital per dollar of growth, a quarter more or less | $142 | $153 |
| Return on new capital after year ten, at the rate or one step up | $149 | $185 |
| The rate, a point higher or lower | $116 | $204 |
| Long-run growth a point lower | $145 | - |
Value a share as growth and margin change
| Normal margin ↓ · growth → | 50% | 75% | 100% | 125% | 150% |
|---|---|---|---|---|---|
| 21.3% | $79.05 | $95.93 | $116 | $140 | $167 |
| 23.9% | $89.74 | $109 | $132 | $160 | $192 |
| 26.6% | $100 | $123 | $149 | $180 | $216 |
| 29.3% | $111 | $136 | $165 | $200 | $241 |
| 31.9% | $122 | $149 | $182 | $220 | $266 |
Growth is shown as a share of the base case's. Green: the price is at or under 80% of that value. Red: at or over 120%.
How we read the multiple
On sales, Onto is the cheapest of the rivals its own annual report names. On operating profit it is dearer: about 43 times a year's profit once its $1.5B of convertible debt is counted, against about 35 for rivals when last checked.
It earns 3.4% on the money invested in it, against 7.4% over its past six years and 10.0% for rivals, a figure the strong quarter has not yet lifted.
So the price bets that the record margin is a run rate, not a peak.
Against its own history. Above its own normal on the ratios last checked, before the strong quarter lifted its trailing profit.
The evidence under this - 3 claims
- 2026-11-05editedRe-struck at the 2026-11-04 close of 184.82 from a pack fetched 2026-11-05 (price down 31% from 268.01): EV/EBIT 66.4 against a cohort median of 35.3, nearly twice rather than more than twice; still cheapest on price to sales and to book.
- 2026-11-09editedre-struck at the 6 November close on trailing operating income of $206M after the Q3 print; cohort medians not refreshed
- 2026-11-10editedThe 35 times it quoted left the $1.5B of convertible notes out of company value; with them Onto is about 43 times at the 6 November close, above the cohort median
- Annualising the third-quarter GAAP operating income guide of $81.4-89.7 million gives roughly 26 times company value at the 6 November close and 29 at the 9 November one, below the cohort's trailing median of 35. If the guided quarter is the run rate the premium is already gone.
- The notes are convertible and an if-converted reading would swap $1.5B of debt for about 3.9 million shares; the 10-Q says the notes were not in the money at 30 September, so they are carried as debt here.
- 2026-11-05editedRe-struck at the 2026-11-04 close from a pack fetched 2026-11-05: EV/EBIT 66.4 against a cohort median of 35.3, from 96.9 against 45.0 at 2026-09-04. The cohort fell about 22% in the same weeks, so the gap narrowed from 2.2 times to 1.9 times.
- 2026-11-09editedre-struck at the 6 November close after the Q3 print lifted trailing operating income to $206M
- 2026-11-10editedCompany value now includes the $1.5B of 2031 convertible notes the 9 November version left out of the bridge; 35 times was struck on cash alone
Priced against its rivals
The competitors its own annual report names, each confirmed against the rival's filing. Measured on company value for each $1 of operating profit, cheapest first:
| Ticker | Company | company value for each $1 of operating profit |
|---|---|---|
| KLAC | KLA | 32.3× |
| CAMT | Camtek | 35.3× |
| NVMI | Nova | 36.4× |
| ONTO | Onto Innovation | 66.4× |
The middle of the other 3 is 35.3. Onto Innovation Inc. is dearest of 4.
Rivals' figures come from a data provider, so read the spread of the group rather than any single pair.
Above the group on operating profit as last checked, once debt is counted; rivals' September figures are not yet in.
Private or foreign rivals that cannot be priced: Ushio, Inc., Canon, Inc., GigaVis Co. Ltd.
Where we disagree with the market
A record quarter, a first $1B backlog and AI-driven demand make Onto a clear winner in chip inspection.
The margin has arrived, but a tenth of sales still goes on charges the company has taken every year for four years, and it guides a fifth.
The adjusted number is the one everyone quotes. The difference appears only by adding up four years of restructuring from the notes to the accounts, and recent purchases add a yearly write-off of what was bought on top.
We would be wrong if the December quarter's reported margin lands in the promised band and restructuring falls below $10M, or if management dates the end of the programme.
What analysts say, and the evidence
The evidence under this - 4 claims
- 2026-11-09editedQ3 2026 release: nine-month figure and the higher fourth-quarter guide
- The company guided first-quarter 2026 GAAP diluted EPS to $0.74-$0.84 and delivered $0.67, below its own range, while the non-GAAP figure beat its range - so the GAAP half of this guidance has missed once in the last two quarters it was given.
- Restructuring has been guided as ending, and has instead risen in each of the last three fiscal years.
- 2026-11-05editedIts valid_through of 2026-11-05 comes before the print: the company dates Q3 results to 9 November (release of 2026-10-19; FMP calendar), so the guide stands until then.
- 2026-11-09editedthe print answered the guide: margin above the band and restructuring below it
- The company's GAAP guide missed once in the last two quarters it was given, in the first quarter, and met it in the third.
- Restructuring was guided to fall and has instead risen in each of four years; $18-22 million is above the third quarter's $12.1 million.
- 2026-11-09editedRe-struck on the decaying fade the owner chose on 9 November: after the stated path each year closes 30% of the gap to 4%, and an analysts' margin is cut by their gap to the filed operating profit.
- 2026-11-09editedthe business re-valued in three stages at an 8% required return, with analysts' margins put on the filed basis, after the day's review
What could go wrong, and how we would know
The risks
- Charges that never end. Restructuring has been booked four years running. A fourth year carried into 2027 with no end date would make it part of the business.
- Ground lost in packaging. Tool sales fell in 2025 on fewer AI packaging inspection units, while Camtek, a rival, gets half its sales from AI.
- A $720M minority bet. Onto owns 27% of Rigaku, valued at market prices and outside its control; a write-down would hit earnings.
- Few, large customers. Three customers took 49% of 2025 sales, and the biggest new deal is with one memory maker.
The evidence under this - 6 claims
- 2026-11-09editedQ3 2026 release: nine-month figure and the higher fourth-quarter guide
- Camtek's revenue is a fifth of Onto's, so it can grow off a smaller base without Onto losing absolute share.
- Onto's own advanced packaging revenue reached a record in the second quarter of 2026, so whatever happened in FY2025 has reversed at least once.
- Management framed the stake as self-funding: foregone interest income offset by licensing revenue plus about $7 million of Rigaku dividends.
- The stake buys access to X-ray metrology that Onto's own chief executive placed several device generations out, so the operating return is deferred rather than absent.
- The counterparty is not named, the agreement is not filed as an exhibit, and the value is described as an estimate rather than a committed minimum.
- A volume purchase agreement in semiconductor equipment typically sets pricing against expected volumes rather than obliging the buyer to take them.
What we still do not know
- Which product lines earn the money. Onto reports as one business, with no split by line.
- When the restructuring ends. Management has not dated it.
- What Rigaku will pay back. Management would not size the licensing income it expects from the stake.
The evidence under this - 3 claims
- 2026-11-09editedQ3 2026 release: nine-month figure and the higher fourth-quarter guide
- Management framed the stake as self-funding: foregone interest income offset by licensing revenue plus about $7 million of Rigaku dividends.
- The stake buys access to X-ray metrology that Onto's own chief executive placed several device generations out, so the operating return is deferred rather than absent.
What would change our view
- Unattractive→AttractiveThe price falls 20% under fair value
It needs:
- ○The share price falls to about $119, 80% of what we think the business is worth.about ≈$121.07 today, 34% below the last close
- Unattractive→NeutralThe price falls back within 20% of fair value
It needs:
- ○The share price falls to about $179, back within 20% of what we think the business is worth.about ≈$178.96 today, 3% below the last close
- Unattractive→AttractiveThe margin comes back
It needs all of:
- ○Reported operating margin stays above 18% through 2027 while restructuring charges fall below $20M a year.checked at the next results, due in Feb 2027
- ○The return on money invested climbs from 3.4% toward its own six-year normal of 7.4%.checked at the next results, due in Feb 2027
We would also be wrong if
- Restructuring charges exceed $60M again in 2026, which the fourth-quarter guide of $18M to $22M would do, or reported operating margin stays below 18% through the December quarter.
What is coming
- 17 December 2026 Analyst event at the New York Stock Exchange: Whether management dates the end of the restructuring programme and sets a GAAP margin target, and how it means to earn a return on Rigaku and Semilab.
Every dated event ahead
- 17 December 2026 Analyst event at the New York Stock Exchange: Whether management dates the end of the restructuring programme and sets a GAAP margin target, and how it means to earn a return on Rigaku and Semilab.
- February 2027 Q4 and full-year 2026 results and the FY2026 10-K: Whether GAAP operating margin reaches the guided 24.4%-24.8% with restructuring inside $18-22 million, and whether a fifth year of restructuring is guided.
Since we wrote this
- 17 NovNewsOnto authorises $400M of buybacks, replacing its 2024 programme; nothing spent yet. View held$400 million share repurchase authorised.
- 10 NovEarningsCall read; debt counted, value near $165, still NeutralThe call gave no end date for the charges. Counting the $1.5B of convertible notes puts our value near $165 and the price at about 118% of it.
- 10 NovThesis reviewMoved to Unattractive: priced at 130% of a value near $149Re-valued on the owner's rules of 10 November, with the return on new capital gliding to its long-run level.
- 9 NovEarningsQ3 margin hit 23.3%, above the band; charges guided upRevenue rose 88% and the margin test passed. The fourth quarter is guided to more restructuring, so the route to Attractive stays closed.
- 9 NovThesis reviewStill Neutral: priced at 84% of a value near $207Re-valued in three stages at an 8% return, the method now drawn on every thesis: the price sits inside the 20% margin of safety.
- 5 NovPrice moveShares down 31%; the profit multiple re-struck at 66 against 35The fall came with no company news and the whole peer group re-rated down. Onto is still nearly twice the rivals' multiple of operating profit, so the view holds until the 9 November results.
- 5 OctThesis reviewThe long case now sits under the verdictAfter the five-name pilot, the owner asked for the long case on every thesis.
- 4 OctThesis reviewOwner's checklist: revenue streams, cost of growth, management, catalystsThe owner's checklist found the method silent on who runs the company, what growth costs, where the money comes from and what is dated ahead; this pass fills those four blocks from the proxy and filings.
- 6 SepThesis writtenNeutral, medium convictionCheapest of its named rivals on sales and dearest on profit, because charges running at about a tenth of sales keep the reported margin down. Management says they will fall.
Also checked 6 times with nothing new to act on.
Sources 21
Sources - 21
Every claim above cites one of these, or states the reasoning that derived it. The quote is frozen at the date it was read: a link can rot, and an agent fetch returns a reading of a page rather than the page. Backs counts the whole claim ledger, so it can name a claim this page does not surface.
- S01primarycompany filing2026-02-24Item 1 business and named competitors, customer concentration table, the three-year restructuring table split between cost of goods sold and operating expenses, revenue by source, the Semilab purchase price allocation, single-segment statementbacksC01C02C03C05C06C07C10C15C16C26C31C32C33C37C39C43
- S02primarycompany filing2026-08-06Note 15 restructuring split, Note 2 on the Rigaku share purchase agreement, legal matters, share repurchase detail, the segment table, the new headquarters leasebacksC02C06C07C09C20C22C34C36C38C39
- S03primarycompany filing2026-08-06the full GAAP-to-non-GAAP reconciliation for the quarter, half and prior-year comparatives, the balance sheet, the third-quarter outlook with its own reconciliation, and the backlog statementbacksC04C05C08C09C19C21C22
- S04primarycompany filing2026-02-19FY2025 and Q4 2025 GAAP and non-GAAP results, the first-quarter 2026 guidance that Q1 later missed on GAAP, and the volume purchase agreement with an HBM manufacturerbacksC03C18C23
- S05primarycompany filing2026-05-21conversion price, capped call terms and cost, the concurrent share repurchase price, and the stated intention to fund the Rigaku acquisitionbacksC19
- S06primarycompany filing2026-08-10the closing, the yen and dollar consideration, the fair value option accounting and the statement that Rigaku will not be consolidatedbacksC20C21
- S07primarytranscript2026-05-05First quarter 2026 earnings call transcriptmanagement's answers on the Dragonfly G5 head-to-head win, the panel opportunity and the Rigaku economics; nine analyst questions, which are a separate origin from the answers
We are seeing things now below 200 nanometers, where historically, 800 nanometers might have been about the limit.
backsC30 - S08primarycompany filing2026-08-06the largest process-control supplier's own segment revenue, its GAAP operating margin, and its Competition section naming Onto Innovation - evidence about Onto from outside OntobacksC05C24
- S09primarycompany filing2026-02-17a competitor's own description of the same product sold to the same buyers, confirming cohort membershipbacksC25
- S10primarycompany filing2026-03-19a competitor's own statement that roughly half its revenue serves AI applications including HBM and advanced packaging - the market Onto's inspection volume fell inbacksC25C26
- S11primaryindustry data2026-07-14the rate behind machine.current, measured by the industry's own trade association rather than by any supplier in it
the Wafer Fab Equipment (WFE) segment...is projected to increase 23.1% to $143.9 billion in 2026.
backsC27 - S12primaryindustry data2026-07-14the memory half of the driver, which is where Onto's HBM-linked advanced packaging demand sits
DRAM equipment sales are projected to rise 39.0% to $38.8 billion in 2026
backsC27 - S13primaryvendor data2026-09-06Research pack, frozen at content/ONTO/research-pack.jsonprice, returns, the analyst split, the volatility bucket, insider and short-interest filings, and the competitors:filed cohort multiplesbacksC05C14C23C29
- S14primarycompany filing2026-04-06beneficial ownership as of March 24, 2026, the executive officers and their start dates, the FY2025 cash bonus goals and payouts, the PSU design on relative TSR against the SOXbacksC40C41C42
- S15primarycompany release2026-08-10the date of the company's analyst event; the Business Wire original refuses this repository's client, so the release was read through press_fetch.py from a syndicated copy
Onto Innovation Inc. (NYSE: ONTO) (“Onto Innovation,” “Onto,” or the “Company”) today announced that it will host a Company-sponsored Analyst Event on Thursday, December 17, 2026, at the New York Stock Exchange in New York City.
backsC44 - S16secondaryvendor data2026-11-05ONTO research pack (market and vendor tiers) fetched 2026-11-05 - valuation series and competitors:filed cohort table, through the 2026-11-04 close of 184.82EV/EBIT 66.4 against a cohort median of 35.3 (KLA 32.3, Camtek 35.3, Nova 36.4); price to sales 8.1 against a six-year median of 7.2, price to book 4.7 against 3.7, price to earnings 69.0 against 50.7, EV to sales 8.3 against 7.0; the cohort's price to sales 9.8, EV to sales 10.6 and price to book 6.3 at the median; return on invested capital unchanged at 3.4%.backsC12C13C35
- S17primarycompany release2026-11-09third-quarter revenue, GAAP and non-GAAP margins, the restructuring line, cash, backlog and the fourth-quarter outlookbacksC06C08C12C13C17C35C45C46
- S18primarycompany filing2026-11-09trailing revenue, operating profit, stock pay, tax, debt, cash and the diluted share countbacksC48
- S19secondaryvendor data2026-11-09the analysts' average revenue and operating profit for the next three fiscal years, and the closebacksC47C48
- S20primarytranscript2026-11-09the chief executive's and chief financial officer's remarks and eleven analysts' questions: the fourth-quarter and 2027 outlook, gross margin path, backlog and the Rigaku stakebacksC49
- S21primarycompany filing2026-11-09the balance sheet with the $1.5B of 2031 Notes (note 7), cash and marketable securities of $1.25B, and the nine-month cash flowread, but no claim rests on it